RedHill Biopharma Ltd. (RDHL) Analysts See $-0.65 EPS

February 14, 2018 - By Linda Rogers

 RedHill Biopharma Ltd. (RDHL) Analysts See $ 0.65 EPS

Analysts expect RedHill Biopharma Ltd. (NASDAQ:RDHL) to report $-0.65 EPS on February, 22.They anticipate $0.05 EPS change or 7.14 % from last quarter’s $-0.7 EPS. After having $-0.90 EPS previously, RedHill Biopharma Ltd.’s analysts see -27.78 % EPS growth. The stock increased 0.17% or $0.01 during the last trading session, reaching $5.82. About 34,133 shares traded. RedHill Biopharma Ltd. (NASDAQ:RDHL) has declined 9.09% since February 14, 2017 and is downtrending. It has underperformed by 25.79% the S&P500.

RedHill Biopharma Ltd. (NASDAQ:RDHL) Ratings Coverage

Among 8 analysts covering RedHill Biopharma (NASDAQ:RDHL), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RedHill Biopharma had 14 analyst reports since July 29, 2015 according to SRatingsIntel. TH Capital maintained RedHill Biopharma Ltd. (NASDAQ:RDHL) on Wednesday, July 29 with “Buy” rating. The firm earned “Sell” rating on Saturday, August 22 by Zacks. Northland Capital initiated the shares of RDHL in report on Tuesday, September 29 with “Buy” rating. Roth Capital maintained the shares of RDHL in report on Monday, July 31 with “Buy” rating. The firm has “Buy” rating by Roth Capital given on Tuesday, November 14. FBR Capital maintained the stock with “Outperform” rating in Friday, February 24 report. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, June 15. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) has “Hold” rating given on Tuesday, August 25 by TheStreet. FBR Capital maintained RedHill Biopharma Ltd. (NASDAQ:RDHL) on Thursday, June 15 with “Buy” rating. The firm has “Buy” rating by Nomura given on Tuesday, September 29.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company has market cap of $121.02 million. The firm promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. It currently has negative earnings. The Company’s clinical-stage pipeline includes TALICIA , an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S.

More notable recent RedHill Biopharma Ltd. (NASDAQ:RDHL) news were published by: Benzinga.com which released: “21 Stocks Moving In Friday’s Pre-Market Session” on January 26, 2018, also Benzinga.com with their article: “45 Biggest Movers From Friday” published on January 29, 2018, Benzinga.com published: “Exclusive: RedHill Biopharma CEO Talks Steering His Company Through A Year …” on June 05, 2017. More interesting news about RedHill Biopharma Ltd. (NASDAQ:RDHL) were released by: Marketwatch.com and their article: “RedHill Biopharma reports positive results from mid-stage trial of irritable …” published on October 03, 2017 as well as Marketwatch.com‘s news article titled: “RedHill Biopharma Ltd. ADR” with publication date: March 27, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: